Related Experiment Video
Updated: Aug 25, 2025
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
Published on: March 2, 2014
Using host receptor as a decoy to treat COVID-19: a solution for immune escape?
Kuo-Yen Huang1,2, Ming-Shiu Lin3,4, Pan-Chyr Yang1,3,4
1YongLin Institute of Health, National Taiwan University, Taipei, Taiwan.
Abstract:
There is an unmet clinical need to end the COVID-19 pandemic. In the past 2 years, the SARS-CoV-2 continued to evolve and poses a critical challenge to the efficacy of the vaccine and neutralizing antibody therapies. The fifth wave of the pandemic is driven by the Omicron variants, due to their ability to evade prior immunity and their resistance to therapeutic antibodies. The report by Zhang et al in the current issue of EMBO Molecular Medicine shows that the engineered decoy ACE2 can reduce lung injury and improve survival in K18-hACE2 transgenic mice inoculated with a lethal dose of the SARS-CoV-2 and potentially targets the Omicron variant.
Insights
An engineered decoy ACE2 protein shows promise in reducing lung injury and improving survival in mice infected with SARS-CoV-2, including Omicron variants. This approach offers a potential new strategy against evolving COVID-19.
Area of Science:
- Virology
- Immunology
- Therapeutic Development
Background:
- The ongoing COVID-19 pandemic necessitates new therapeutic strategies due to the continuous evolution of SARS-CoV-2.
- Emerging variants like Omicron evade vaccine-induced immunity and resist existing antibody therapies, posing a significant clinical challenge.
- There is an urgent need for treatments effective against current and future SARS-CoV-2 strains.
Purpose of the Study:
- To investigate the therapeutic potential of an engineered decoy ACE2 protein against SARS-CoV-2 infection.
- To evaluate the efficacy of decoy ACE2 in reducing lung injury and improving survival in a mouse model of lethal SARS-CoV-2 infection.
- To assess the potential of decoy ACE2 to target and neutralize emerging SARS-CoV-2 variants, including Omicron.
Main Methods:
- Utilized K18-hACE2 transgenic mice, a model susceptible to lethal SARS-CoV-2 infection.
- Administered an engineered decoy ACE2 protein to mice inoculated with a lethal dose of SARS-CoV-2.
- Assessed lung injury, viral load, and survival rates in treated versus control groups.
- Evaluated the efficacy of decoy ACE2 against SARS-CoV-2 variants, including Omicron.
Main Results:
- The engineered decoy ACE2 significantly reduced lung injury in SARS-CoV-2 infected mice.
- Treatment with decoy ACE2 improved survival rates in mice challenged with a lethal dose of SARS-CoV-2.
- Preliminary data suggests potential efficacy against Omicron variants, which exhibit immune evasion properties.
Conclusions:
- Engineered decoy ACE2 represents a promising therapeutic candidate for mitigating SARS-CoV-2-induced lung injury and improving survival.
- This strategy may offer a viable treatment option against current and future SARS-CoV-2 variants, including immune-evasive Omicron strains.
- Further research is warranted to explore the clinical application of decoy ACE2 for COVID-19 treatment.
Related Concept Videos
01:29Viruses with RNA Genomes
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...